Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00007189 · ClinicalTrials.gov registry record · Phase 3
Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
A Phase 3 study, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,625
- Enrollment target
NCT00007189: Completed Phase 3 study, sponsored by Seattle Institute for Biomedical and Clinical Research.
NCT00007189 is a Phase 3 study that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 2,625 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (240% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00007189, a Phase 3 study, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,625 participants
- Enrollment target
Study Summary
The purpose of this trial is to test the ability of the non-steroidal anti-inflammatory medications naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline.
Interventions
- DRUG Celecoxib (Celebrex)
- DRUG Naproxen Sodium (Aleve)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,625 participants |
| Start Date | 2001-01 |
| Phase | Phase 3 |
What the finished NCT00007189 record still lists
NCT00007189 is an interventional study that assigns participants to a tested intervention. Its 2,625 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (240% higher).
The record links to 0 conditions, and to 2 interventions - of which Celecoxib (Celebrex) is the first listed.
NCT00007189 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00007189 about?
NCT00007189 is a clinical study titled "Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)". The purpose of this trial is to test the ability of the non-steroidal anti-inflammatory medications naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline.
What is the current status of trial NCT00007189?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,625 participants. The study started on 2001-01.
What interventions are being tested in trial NCT00007189?
The interventions under investigation include: Celecoxib (Celebrex) (DRUG), Naproxen Sodium (Aleve) (DRUG).
Who is sponsoring clinical trial NCT00007189?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00007189's enrollment target sits among peer trials
2,625 84th of 2000 higher than 1,917 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06455085 · 2,634 participants · NA
RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
- NCT06825715 · 2,653 participants · NA
Multilevel Intervention for Precision Oncology
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia